Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Disclosures About Fair Value - Summary of Changes in Fair Value (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 1,945,200
Change in fair value of derivative liability	(338,053)
Amount included in debt discounts	778,900
Reclassification of derivative liability to equity	(306,000)
Ending balance	2,080,047
Conversion Feature [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	1,610,900
Change in fair value of derivative liability	(382,700)
Amount included in debt discounts	778,900
Reclassification of derivative liability to equity	(239,800)
Ending balance	1,767,300
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	334,300
Change in fair value of derivative liability	44,647
Reclassification of derivative liability to equity	(66,200)
Ending balance	$ 312,747